[go: up one dir, main page]

HK1169941A1 - 治療外周血管疾病的組合物 - Google Patents

治療外周血管疾病的組合物

Info

Publication number
HK1169941A1
HK1169941A1 HK12110622.1A HK12110622A HK1169941A1 HK 1169941 A1 HK1169941 A1 HK 1169941A1 HK 12110622 A HK12110622 A HK 12110622A HK 1169941 A1 HK1169941 A1 HK 1169941A1
Authority
HK
Hong Kong
Prior art keywords
compositions
vascular disease
peripheral vascular
treating peripheral
treating
Prior art date
Application number
HK12110622.1A
Other languages
English (en)
Inventor
Crist J Frangakis
Harry J Leighton
Original Assignee
Exodos Life Sciences Ltd Partnership
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exodos Life Sciences Ltd Partnership filed Critical Exodos Life Sciences Ltd Partnership
Publication of HK1169941A1 publication Critical patent/HK1169941A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK12110622.1A 2009-12-18 2012-10-25 治療外周血管疾病的組合物 HK1169941A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28796709P 2009-12-18 2009-12-18
PCT/US2010/061054 WO2011075655A1 (en) 2009-12-18 2010-12-17 Methods and compositions for treating peripheral vascular disease

Publications (1)

Publication Number Publication Date
HK1169941A1 true HK1169941A1 (zh) 2013-02-15

Family

ID=44167718

Family Applications (1)

Application Number Title Priority Date Filing Date
HK12110622.1A HK1169941A1 (zh) 2009-12-18 2012-10-25 治療外周血管疾病的組合物

Country Status (8)

Country Link
US (3) US20130053393A1 (zh)
EP (1) EP2512479B1 (zh)
JP (2) JP5960061B2 (zh)
AU (1) AU2010330813B2 (zh)
CA (1) CA2784788A1 (zh)
DK (1) DK2512479T3 (zh)
HK (1) HK1169941A1 (zh)
WO (1) WO2011075655A1 (zh)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011075691A1 (en) 2009-12-18 2011-06-23 Exodos Life Sciences Limited Partnership Methods and compositions for stable liquid drug formulations
JP5883852B2 (ja) * 2010-05-26 2016-03-15 アドヴェリオ・ファーマ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 全身性強皮症（ＳＳｃ）を処置するためのｓＧＣ刺激剤、ｓＧＣアクチベーター単独およびＰＤＥ５阻害剤との組み合わせ剤の使用
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
EP2753332B1 (en) * 2011-09-09 2017-02-15 SK Chemicals Co., Ltd. Mridenafil for reducing skin wrinkles
EP3024455A1 (en) 2013-07-25 2016-06-01 Bayer Pharma Aktiengesellschaft Sgc stimulators or sgc activators and pde5 inhibitors in combination with additional treatment for the therapy of cystic fibrosis
CN104644579A (zh) * 2013-11-25 2015-05-27 天津市汉康医药生物技术有限公司 一种阿伐那非药物组合物
JP6236304B2 (ja) * 2013-12-04 2017-11-22 ライオン株式会社 涙液分泌促進剤
JP6211406B2 (ja) * 2013-12-04 2017-10-11 ライオン株式会社 ムスカリン受容体活性化剤及び唾液分泌促進剤
EP3082428A4 (en) 2013-12-09 2017-08-02 Respira Therapeutics, Inc. Pde5 inhibitor powder formulations and methods relating thereto
JP2017524705A (ja) 2014-08-12 2017-08-31 メジオン ファーマ カンパニー リミテッド ウデナフィル組成物を用いてフォンタン患者における心筋性能を改善する方法
EP3226972A4 (en) 2014-12-01 2018-08-08 Achelios Therapeutics, Inc. Methods and compositions for treating migraine and conditions associated with pain
CA2984983A1 (en) * 2015-05-06 2016-11-10 Bayer Pharma Aktiengesellschaft The use of sgc stimulators, sgc activators, alone and combinations with pde5 inhibitors for the treatment of digital ulcers (du) concomitant to systemic sclerosis (ssc)
US9993447B2 (en) * 2015-09-14 2018-06-12 JW Nutritional, LLC Systems and methods for increasing agmatine cellular uptake by oral administration
EP3377495B1 (en) 2015-11-16 2022-03-16 Topadur Pharma AG 2-phenyl-3,4-dihydropyrrolo[2,1-f] [1,2,4]triazinone derivatives as phosphodiesterase inhibitors and uses thereof
WO2018167687A1 (en) 2017-03-14 2018-09-20 Atir Holding S.A. Use of heterocyclic compounds in the treatment of pigmented skin
EP3595623B1 (en) 2017-03-14 2024-05-01 Atir Holding S.A. Topical formulation for the treatment of pigmented skin
RU2758373C2 (ru) 2017-05-22 2021-10-28 Топадур Фарма Аг Новые активаторы растворимой гуанилатциклазы и ингибиторы фосфодиэстеразы с двойным механизмом действия и их применение
US11117808B2 (en) * 2017-08-01 2021-09-14 University Of Georgia Research Foundation, Inc. Mesoporous nitric oxide-releasing silica particles, methods of making, and uses thereof
KR20190043369A (ko) * 2017-10-18 2019-04-26 주식회사 코아팜바이오 유데나필의 신규한 반고형 제제
MX2017016930A (es) * 2017-12-19 2019-06-20 Malesil Research & Tech Llc Uso del maleato de sildenafil en el tratamiento de ulceras de pie diabetico.
CN112423736A (zh) 2018-06-01 2021-02-26 塔凡塔医疗匈牙利公司 用于治疗肛门直肠疾病的局部氨氯地平盐
MX2021001503A (es) * 2018-08-06 2021-04-28 Nicox Sa Inhibidor de fosfodiesterasa tipo 5 con liberacion de oxido nitrico.
MX2021005892A (es) 2018-11-28 2021-06-23 Topadur Pharma Ag Novedosos activadores de guanilato ciclasa soluble e inhibidores de fosfodiesterasa con modo de accion dual y usos de estos.
WO2020123312A1 (en) 2018-12-09 2020-06-18 Weinberg Assa Method to prevent and treat macular degeneration by vasodilators
WO2021245192A1 (en) 2020-06-04 2021-12-09 Topadur Pharma Ag Novel dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof
WO2022115576A2 (en) * 2020-11-25 2022-06-02 Aisa Pharma, Inc. Treatment of raynaud's disease
US11185513B1 (en) * 2021-05-07 2021-11-30 King Abdulaziz University Transfersome-containing transdermal film formulations and methods of use
JP2024536047A (ja) 2021-09-29 2024-10-04 トパデュール ファルマ アーゲー ２－フェニル－３，４－ジヒドロピロロ［２，ｌ－ｆ］［１，２，４］トリアジノン誘導体の局所組成物及びその使用
CN118891047A (zh) 2022-03-02 2024-11-01 托帕杜制药公司 外用组合物及其应用
KR20230129639A (ko) 2022-03-02 2023-09-11 연세대학교 산학협력단 이중작용 pde5 억제제/질산유기에스터의 국소 혈류 증진을 위한 경피 투약 형태

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7914814B2 (en) * 1997-09-17 2011-03-29 Strategic Science & Technologies, Llc Topical delivery of arginine of cause beneficial effects
US6395736B1 (en) * 1998-12-14 2002-05-28 Cellegy Pharmaceuticals, Inc. Compositions and methods for the treatment of anorectal disorders
US20040110843A1 (en) * 2000-01-10 2004-06-10 Nexmed (Holdings), Inc. Methods of treatment of male erectile dysfunction
US20030105108A1 (en) * 2002-12-19 2003-06-05 Wood Ralph E. Method of treating peripheral vascular diseases, peripheral neuropathies, and autonomic neuropathies
US7737147B2 (en) * 2000-07-27 2010-06-15 Thomas Nadackal Thomas Methods and compositions to enhance the efficacy of phosphodiesterase inhibitors
US6538033B2 (en) 2000-08-29 2003-03-25 Huntington Medical Research Institutes Nitric oxide donor compounds
ATE421500T1 (de) * 2002-05-09 2009-02-15 Baker Med Res Inst Aminosäureanaloga
US20020168424A1 (en) * 2002-07-31 2002-11-14 Dr. Mohsen Shahinpoor Nitric oxide (NO) donor+cGMP-PDE5 inhibitor as a topical drug for glaucoma
US20020182162A1 (en) * 2002-08-07 2002-12-05 Mohsen Shahinpoor Nitric oxide (NO) donor+cGMP-PDE5 inhibitor as a topical drug for enhanced hair growth
AU2005218539A1 (en) * 2004-03-01 2005-09-15 Lumen Therapeutics, Llc Compositions and methods for treating diseases
HUP0401422A2 (en) * 2004-07-15 2006-04-28 G Laszlo Meszaros Use of l-arginine as vasoaktive ingredient absorbing through skin for external application
AU2006263669B9 (en) * 2005-06-29 2012-12-13 Mars, Incorporated Inducing peripheral blood vessel vasodilation
WO2010062366A1 (en) * 2008-10-31 2010-06-03 Arginetix, Inc. Compositions and methods of treating endothelial disorders

Also Published As

Publication number Publication date
CA2784788A1 (en) 2011-06-23
AU2010330813B2 (en) 2016-04-28
US20130053393A1 (en) 2013-02-28
EP2512479B1 (en) 2016-03-30
EP2512479A4 (en) 2013-07-17
AU2010330813A2 (en) 2012-08-09
US20180036314A1 (en) 2018-02-08
DK2512479T3 (en) 2016-06-06
EP2512479A1 (en) 2012-10-24
US20150031704A1 (en) 2015-01-29
JP2016166178A (ja) 2016-09-15
JP5960061B2 (ja) 2016-08-02
AU2010330813A1 (en) 2012-08-09
WO2011075655A1 (en) 2011-06-23
JP2013514995A (ja) 2013-05-02

Similar Documents

Publication Publication Date Title
HK1169941A1 (zh) 治療外周血管疾病的組合物
ZA201505556B (en) Compositions for treating gaucher disease
EP2464219A4 (en) MULTI-TRANSGENIC PIGS FOR DIABETES TREATMENT
IL207892A0 (en) Agent for treating disease
HK1151533A1 (zh) 種治療疾病的試劑
ZA201007215B (en) Agent for treating disease
EP2409634A4 (en) ENDOSCOPE OF TREATMENT
HK1170490A1 (zh) 用於青光眼的治療或預防的醫藥組合物
EP2429584A4 (en) TREATMENT PROCEDURE AND COMPOSITIONS
EP2411006A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF RENAL DISORDERS
GB0908193D0 (en) Treatment of disease state
ZA201204845B (en) Agents for treating disease
HK1154797A1 (zh) 治療疾病的成分
SG10201408508YA (en) Combination composition useful for treating cardiovascular diseases
GB0900599D0 (en) Treatment
EP2174956A4 (en) COMPOSITIONS FOR ANTIFIBRINOLYSIS THERAPY
EP2410846A4 (en) GLYCOLIPIDES AS TREATMENT OF DISEASES
ZA201204341B (en) Pharmaceutical composition for treating gutaneous burns
PL2263454T3 (pl) Kompozycja uzdatniająca
GB201001521D0 (en) Treatment
GB0913968D0 (en) Treatment
GB0900786D0 (en) Therapeutic compositions
GB0920940D0 (en) Agent for treating disease
GB0920942D0 (en) Agent for treating disease
GB0920933D0 (en) Agent for treating disease

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20201211